Analyst Price Targets — JNJ
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 3, 2026 2:33 pm | — | RBC Capital | $255.00 | $233.35 | TheFly | Johnson & Johnson price target raised to $255 from $240 at RBC Capital |
| January 28, 2026 6:02 am | Terrance Flynn | Morgan Stanley | $262.00 | $224.44 | StreetInsider | Morgan Stanley Upgrades Johnson & Johnson (JNJ) to Overweight |
| January 27, 2026 2:38 pm | Ilya Zubkov | Loop Capital Markets | $220.00 | $225.16 | StreetInsider | Johnson & Johnson (JNJ) PT Raised to $220 at Freedom Capital Markets |
| January 23, 2026 11:43 am | Vamil Divan | Guggenheim | $240.00 | $218.49 | TheFly | Johnson & Johnson price target raised to $240 from $227 at Guggenheim |
| January 22, 2026 3:19 pm | — | Scotiabank | $265.00 | $220.18 | TheFly | Johnson & Johnson price target raised to $265 from $230 at Scotiabank |
| January 22, 2026 1:11 pm | Terence Flynn | Morgan Stanley | $200.00 | $220.37 | TheFly | Johnson & Johnson price target raised to $200 from $197 at Morgan Stanley |
| January 22, 2026 12:37 pm | Rick Wise | Stifel Nicolaus | $220.00 | $218.01 | TheFly | Johnson & Johnson price target raised to $220 from $205 at Stifel |
| January 22, 2026 12:25 pm | Asad Haider | Goldman Sachs | $250.00 | $218.01 | TheFly | Johnson & Johnson price target raised to $250 from $240 at Goldman Sachs |
| January 22, 2026 11:21 am | — | Wells Fargo | $240.00 | $218.01 | TheFly | Johnson & Johnson price target raised to $240 from $230 at Wells Fargo |
| January 9, 2026 11:49 am | Lee Hambright | Bernstein | $208.00 | $205.75 | TheFly | Johnson & Johnson price target raised to $208 from $193 at Bernstein |
Latest News for JNJ
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 14th to review first-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer…
AbbVie says 55% of Crohn's patients reached remission in a late-stage study, boosting Skyrizi's outlook amid market competition.
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, BAYRY and Sanofi are worth retaining as the industry shows some recovery.
Davis R M Inc. decreased its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 1.4% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 215,437 shares of the company's stock after selling 3,013 shares during the quarter. Davis
Aprio Wealth Management LLC grew its stake in shares of Johnson and Johnson (NYSE: JNJ) by 36.0% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,783 shares of the company's stock after purchasing an additional 3,117 shares during the quarter.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.